title: The susceptibility of Helicobacter pylori to the rifamycin, rifaximin.
abstract: Forty strains of Helicobacter pylori had an MIC(50) of 4 mg/L of the non-absorbably antibiotic, rifaximin. Neither synergy nor antagonism was demonstrated when the drug was combined with ampicillin, metronidazole and omeprazole and the rate of spontaneous mutation was less than 1 in 10(8). With these in-vitro characteristics, rifaximin should now be assessed for clinical efficacy.
authors.affiliation: Department of Medical Microbiology, University College London Medical School, UK.
authors.forename: J
authors.initials: J
authors.lastname: Holton
authors.forename: D
authors.initials: D
authors.lastname: Vaira
authors.forename: M
authors.initials: M
authors.lastname: Menegatti
authors.forename: L
authors.initials: L
authors.lastname: Barbara
mesh_terms: D000667:Ampicillin / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000494:pharmacology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009853:Omeprazole / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin
chemical_list: D012294:Rifamycins; D008795:Metronidazole; D000667:Ampicillin; D009853:Omeprazole; D000078262:Rifaximin